Solid organ transplant recipients have an increased risk of lip cancer, but the reasons are uncertain. Using data from the Transplant Cancer Match Study, we describe the epidemiology of lip cancer among 261 500 transplant recipients in the United States.
Solid organ transplant recipients have an increased risk of lip cancer, but the reasons are uncertain. Using data from the Transplant Cancer Match Study, we describe the epidemiology of lip cancer among 261 500 transplant recipients in the United States.
Two hundred thirty-one lip cancers were identified, corresponding to elevated risks for both invasive and in situ lip cancers (standardized incidence ratios of 15.3 and 26.2, respectively). Invasive lip cancer incidence was associated with male sex (adjusted incidence rate ratio [aIRR] 2.01, 95% CI 1.44-2.82), transplanted organ (0.33, 0.20-0.57, for liver transplants and 3.07, 1.96-4.81, for lung transplants, compared with kidney transplants), and racial/ethnic groups other than non-Hispanic whites (0.09, 0.04-0.2). In addition, incidence increased with age and during the first 3 years following transplant, and was higher in recipients prescribed cyclosporine/ azathioprine maintenance therapy (aIRR 1.79, 95% CI 1.09-2.93, compared with use of tacrolimus/mycophenolate mofetil) and following a diagnosis of cutaneous squamous cell carcinoma (4.21, 2.69-0.94). The elevation in lip cancer incidence is consistent with an effect of immunosuppression. Notably, the very strong associations with white race and history of prior skin cancer point to an important role for ultraviolet radiation exposure, and cyclosporine and azathioprine may contribute as photosensitizing or DNA damaging agents.
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| INTRODUC TI ON
In the United States, nearly 30 000 individuals receive a transplant yearly, and more than 300 000 Americans are living with a solid organ transplant. 1 The success of transplantation relies on the use of immunosuppressive medications to prevent organ rejection.
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However, the general inhibition of the immune system makes patients more susceptible to infections and cancer. 2 Following transplantation, cancer risk increases two-to three-fold compared to the general population. 3 Risks are especially increased for cancers associated with viral infections, such as non-Hodgkin lymphomas (caused by Epstein-Barr virus) and anogenital cancers (caused by human papillomavirus [HPV] ). [4] [5] [6] [7] Transplant recipients have a markedly elevated risk of lip cancer, with standardized incidence ratios (SIRs) from different countries indicating 13-to 66-fold increased incidence compared with the general population. 3, 6, [8] [9] [10] [11] [12] Lip cancers occur on either the external lip (vermillion border) or the mucosal lip (internal surface, contiguous with the oral cavity) and are predominantly squamous cell carcinomas (SCCs). 13, 14 Ultraviolet radiation (UVR) is an important cause of cancers of the external lip, 15 while mucosal lip cancers are related to alcohol and tobacco consumption. 16 There has been interest in whether HPV may contribute to some cases, although results are inconclusive. 17, 18 Among transplant recipients, elevated lip cancer risk has been associated with UVR exposure, use of cyclosporine or azathioprine as maintenance immunosuppressive therapy, higher dose and prolonged duration of immunosuppression, and increasing time since transplantation.
14,19
However, as lip cancer is a rare malignancy, there are consequently few studies on lip cancer among transplant recipients, 14, 19 and risk factors are not well documented. In the present study, we used data from the Transplant Cancer Match (TCM) Study to describe the epidemiology of lip cancer among transplant recipients in the United States. We used Poisson regression to estimate adjusted incidence rate ratios (aIRRs) mutually adjusted for all of the evaluated demographic and clinical factors (Table 3) . Cutaneous BCC and SCC diagnoses were considered time-dependent variables in the Poisson model.
| MATERIAL S AND ME THODS
Because the associations with age at transplant and time since transplant appeared nonlinear, we assessed models using cubic splines.
These suggested a single change in slope for these variables, so we fitted the relationships using piecewise linear models with a single knot (age at transplant: knot at 20 years old; time since transplant: knot at 3 years).
We also show aIRRs separately for invasive external and mucosal lip SCC. Finally, in an analysis restricted to non-Hispanic whites (among whom most cases occurred), we used backwards selection to identify significant independent risk factors for invasive lip SCC.
Stata (release 15, StataCorp, College Station, TX) and SAS (version 9.3, SAS Institute, Cary, NC) were used for statistical analyses.
| RE SULTS
The study included 261 500 individuals who received 283 832 organ transplants, contributing 1.43 million person-years of follow-up (median 3.96 years, interquartile range 1.43-7.55). As shown in Table 1 , transplant recipients were predominantly males (61.5%) and nonHispanic whites (62.5%), with a median age at transplant of 49 years.
The most common transplanted organ was the kidney (58%) followed by the liver (21.8%), heart (9.5%), and the lung (4.6%).
Overall, 231 lip cancers were diagnosed during follow-up (incidence 16.2 per 100 000 person-years). Of these, 206 were invasive cancers (89.2%) and 25 were in situ cases (10.8%). Both invasive and in situ lip cancers were predominantly SCCs (98.5% and 88%, respectively), with the external lip the most common subsite (82.3%
and 77.3% of invasive and in situ cases, respectively). The majority of invasive lip cancers were diagnosed at localized stage (90.8%), while the remainder had regional (1.5%), distant (0.5%), or unspecified stage (7.3%). Figure 1A) , and the median age at diagnosis of invasive lip SCC was 50 years. The pattern incidence can also be seen in Table 3 , where aIRRs indicate increases in incidence of 41% per year of age up to age 20 (aIRR 1.41, 95% CI 0.96-2.09) and 1% per year of age subsequently (aIRR 1.01, 95% CI 1.00-1.02). As shown in Figure 1B and Table 3 , incidence increased strongly in the first 3 years after transplantation at 71% per year (aIRR 1.71, 95% CI 1.4-2.08). After the first 3 years, incidence appeared to level off, and in the adjusted models this corresponded to a slight decrease of −4% per year (aIRR 0.96, 95% CI 0.92-1).
Incidence declined across calendar periods (p-trend = 0.01, Table 3 ). Incidence was also lower in individuals who received anti-interleukin-2 antibody induction therapy (aIRR 0.47, 95% CI 0.24-0.94) compared to those who did not receive induction therapy. Among baseline maintenance immunosuppressive regimens, incidence was higher for individuals who received cyclosporine and/or azathioprine (aIRR 1.79, 95% CI 1.09-2.93) compared to those who had only received tacrolimus and/or mycophenolate mofetil.
A diagnosis of cutaneous SCC was associated with increased incidence of lip cancer (aIRR 4.21, 95% CI 2.69-6.58). Although incidence was also higher in recipients with cutaneous BCC (Table 3) , there was no association after multivariate adjustment (aIRR 0.95, 95% CI 0.47-1.91). Finally, UVR exposure as assessed by residence at the time of listing/transplantation was not associated with lip cancer incidence ( Table 3 ). In addition, we found no interaction between cyclosporine/azathioprine use and UVR exposure with respect to the incidence of lip SCC (not shown).
Since most invasive SCCs were located on the external lip, aIRRs were similar for invasive external SCC of the lip for most risk factors (Table 3) . For invasive SCC of the mucosal lip, there were few cases (N = 29), so most aIRRs were not precisely estimated. However, the pattern was largely similar to that for external lip SCC, with the possible exception of an attenuated association with cutaneous SCC (aIRR 1.49, 95% CI 0.32-6.94). Of note, incidence of mucosal lip SCC was strongly increased among recipients who received cyclosporine/azathioprine as baseline maintenance therapy compared to a tacrolimus/mycophenolate mofetil regimen (aIRR 5.24, 95% CI 1.14-24.2). Table 4 presents independent risk factors for invasive SCC of the lip among non-Hispanic white recipients. As UVR exposure, induction therapy, and cutaneous BCC diagnosis were the least significant variables, they were removed from the final model following backwards selection. Associations for the remaining risk factors were similar in magnitude to those shown in Table 3 , for SCC overall, SCC of the external lip, and SCC of the mucosal lip.
| D ISCUSS I ON
With the increasing success of transplantation, recipients are living longer with functional grafts. However, use of immunosuppressive medications is associated with adverse effects, including susceptibility to development of some cancers. In our study of more than 260 000 US transplant recipients, we found an elevated risk of lip cancer, most cases of which were invasive SCCs.
The risk that we observed for invasive lip cancer was very high, corresponding to a 15-fold higher incidence compared with the gen- 
3,23
Thus, while the elevated SIR in both transplant recipients and people with HIV/AIDS supports a role for immunosuppression in the development of lip cancer, the much greater elevation among transplant recipients suggests that additional factors are also important.
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Our results point to an etiologic role for UVR, since many of the significant risk factors for lip cancer were indicators of UVR effects. 
TA B L E 3 (Continued)
The majority of lip cancers were in non-Hispanic whites, and the incidence was much higher among non-Hispanic whites than other racial/ethnic groups. Skin pigmentation is a result of melanocyte activity and provides protection against UVR. 24 In addition, we observed a strong association between diagnosis of a cutaneous SCC and subsequent incidence of lip cancer, as we reported in a previous study that utilized TCM data. 20 BCC was also associated with lip cancer incidence, but the association was attenuated when we adjusted for cutaneous SCC and other factors. UVR is a strong risk factor for cutaneous SCC and BCC in the general population, 25 
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UVR exposure is likely important, but it cannot by itself explain the strong elevation in lip cancer incidence, since transplant recipients as a group are unlikely to be substantially more exposed to UVR than the general population. Although all maintenance medications have a major immunosuppressive effect, at least in part because of non-immunosuppressive effects.
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Metabolism of azathioprine results in the incorporation of 6-thioguanine into DNA, and 6-thioguanine DNA is a chromophore that absorbs ultraviolet A radiation, producing highly damaging reactive oxygen species. 29 Furthermore, use of azathioprine is associated with increased skin sensitivity to UVR. 30 Cyclosporine has been described as a promotor of tumor growth through induction of transforming growth factor β and vascular endothelial growth factor. 31, 32 Cyclosporine also interferes directly with DNA repair. have affected the validity of our risk-factor analyses. To the extent that treatment patterns and registry ascertainment of cancer cases vary, the SIRs assessed in cohort studies in different countries could be affected.
In conclusion, there is a markedly high incidence of lip cancer among transplant recipients. Our analyses support that UVR exposure is an important risk factor, and transplant recipients should 
